Concizumab Biosimilar - Research Grade

Human

TFPI

>1mg/ml

IgG4 - kappa

CHO Cells

Befovacimab Biosimilar - Research Grade (ICH5381), Marstacimab Biosimilar - Research Grade (ICH5671)

https://www.imgt.org/mAb-DB/

ICH3002

P10646

Blue ice

This product is a research-grade biosimilar of concizumab, supplied as an unconjugated non-therapeutic analog of the originator antibody for research use only. It is built around the same molecular target as the innovator drug, tissue factor pathway inhibitor (TFPI), and is provided as a human IgG4 kappa molecule. It is intended as a laboratory reference reagent and is not a clinical drug or a substitute for any approved therapeutic. Concizumab itself is a humanized monoclonal antibody developed as a subcutaneous prophylactic hemostatic rebalancing agent for hemophilia A and B, including patients with inhibitors, and it acts by neutralizing the anticoagulant function of TFPI. As a biosimilar analog, this reagent is well suited to in-vitro and functional characterization work, including target-binding studies, epitope and affinity comparison, neutralization and thrombin-generation assays, and as a positive control or benchmarking standard in assay development. It is manufactured at low endotoxin levels and is available in bulk milligram-to-gram quantities to support scale-dependent research applications. Users should confirm suitability for their specific experimental system before use. Tissue factor pathway inhibitor (TFPI, UniProt P10646) is a Kunitz-type serine protease inhibitor and the principal endogenous regulator of the initiation phase of coagulation. It contains three tandem Kunitz domains: the first (K1) binds and inhibits the factor VIIa-tissue factor complex, the second (K2) binds and inhibits activated factor X (FXa), and the C-terminal region and K3 domain mediate cofactor and cell-surface interactions. By dampening early thrombin generation, TFPI helps maintain hemostatic balance and prevents unregulated clot formation. Reducing TFPI activity shifts this balance toward coagulation, which is the rationale for targeting it in bleeding disorders. Concizumab binds the K2 domain, with its epitope overlapping the predicted FXa contact surface, thereby blocking TFPI-mediated inhibition of FXa and restoring sufficient FXa generation to support hemostasis independent of factor VIII or factor IX status.

Extrinsic pathway inhibitor, EPI, Lipoprotein-associated coagulation inhibitor, LACI, Tissue factor pathway inhibitor, TFPI1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Concizumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Concizumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Concizumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Concizumab that binds TFPI; for research use only.